NCT07326007

Brief Summary

Insertion of copper IUDs is often associated with moderate pain, which may reduce acceptance and continuation rates. Factors such as nulliparity and absence of prior vaginal delivery are known to increase pain perception. Women who have delivered only by cesarean section represent a special subgroup because their cervix has not undergone vaginal dilation and cervical remodeling, making insertion technically more difficult and often more painful. This group has been underrepresented in prior analgesia trials, highlighting an important evidence gap.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
88

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Oct 2025

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 24, 2025

Completed
8 days until next milestone

Study Start

First participant enrolled

October 2, 2025

Completed
3 months until next milestone

First Posted

Study publicly available on registry

January 8, 2026

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 15, 2026

Completed
13 days until next milestone

Study Completion

Last participant's last visit for all outcomes

February 28, 2026

Completed
Last Updated

January 8, 2026

Status Verified

January 1, 2026

Enrollment Period

5 months

First QC Date

September 24, 2025

Last Update Submit

January 3, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • pain during IUD insertion

    Pain intensity measured by a 0-10 Numerical Rating Scale (NRS) immediately after IUD release in the uterine cavity, where 0 = "no pain" and 10 = "worst pain imaginable

    immediately after IUD insertion. at the time if IUD release into the uterine cavity

Secondary Outcomes (2)

  • Clinician-rated ease of insertion

    Immediately after completion of IUD insertion procedure

  • Patient satisfaction

    at the end of procedure before discharge from clinic

Study Arms (2)

Verbal Analgesia

EXPERIMENTAL

Participants randomized to the verbal analgesia group will receive a structured communication protocol delivered by the provider throughout the IUD insertion procedure.participants will receive a structured verbal analgesia technique delivered by the provider throughout the IUD insertion procedure. The method involves using a calm, low-volume voice with steady pitch and a slow rate of speech, maintaining a non-rushed and empathetic manner intended to reduce patient anxiety and modulate pain perception. The communication is scripted to ensure consistency. Before beginning, the provider reassures the patient by saying: "You are safe here; I will guide you through every step. Please take slow, deep breaths with me." During speculum insertion, the provider continues: "You may feel some pressure now; that's normal. Keep breathing slowly." At the time of tenaculum application, the patient is prepared with: "You will feel a pinch on the cervix; it may be uncomfortable, but it will pass quick

Behavioral: Verbal Analgesia

Control - Standard Technique

ACTIVE COMPARATOR

Providers will use a standardized neutral script with brief instructions only (e.g., "I am now placing the speculum," "I am sounding the uterus," "The IUD is being inserted," "The procedure is complete"), delivered without reassurance or supportive phrasing

Behavioral: Providers will use a standardized neutral script with brief instructions only (e.g., "I am now placing the speculum," "I am sounding the uterus," "The IUD is being inserted," "The procedure is complet

Interventions

Participants randomized to the verbal analgesia group will receive a structured communication protocol delivered by the provider throughout the IUD insertion procedure.participants will receive a structured verbal analgesia technique delivered by the provider throughout the IUD insertion procedure. The method involves using a calm, low-volume voice with steady pitch and a slow rate of speech, maintaining a non-rushed and empathetic manner intended to reduce patient anxiety and modulate pain perception. The communication is scripted to ensure consistency. Before beginning, the provider reassures the patient by saying: "You are safe here; I will guide you through every step. Please take slow, deep breaths with me." During speculum insertion, the provider continues: "You may feel some pressure now; that's normal. Keep breathing slowly." At the time of tenaculum application, the patient is prepared with: "You will feel a pinch on the cervix; it may be uncomfortable, but it will pass quickl

Verbal Analgesia

Providers will use a standardized neutral script with brief instructions only (e.g., "I am now placing the speculum," "I am sounding the uterus," "The IUD is being inserted," "The procedure is complete"), delivered without reassurance or supportive phrasing

Control - Standard Technique

Eligibility Criteria

Age18 Years - 45 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Women aged 18-45 years.
  • Desire for Copper T380A IUD.
  • Delivery history limited to cesarean section(s), no vaginal delivery

You may not qualify if:

  • o Current pelvic infection, cervicitis, or vaginitis.
  • Uterine anomalies or fibroids distorting the cavity.
  • Contraindication to copper IUD procedure, and use of any analgesic medication within the last 6-8 hours prior to insertion.
  • Pregnancy or suspected pregnancy.
  • Severe dysmenorrhea requiring narcotics

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Al Gezeera Hospital

Giza, Egypt

RECRUITING

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
principal investigator

Study Record Dates

First Submitted

September 24, 2025

First Posted

January 8, 2026

Study Start

October 2, 2025

Primary Completion

February 15, 2026

Study Completion

February 28, 2026

Last Updated

January 8, 2026

Record last verified: 2026-01

Locations